Meusinvest (Noshaq)

RISORCE fills a need in Belgium for local solutions for processing tire waste while remaining dedicated to a circular economy strategy. We provide a regionally-based, technologically and environmentally sound solution.

IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.

Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacturing of small satellites equipped with advanced sensors. The company focuses on addressing complex challenges through innovative solutions, including the use of artificial intelligence and machine learning to automate various tasks. Aerospacelab's technology enables the collection of high-resolution optical data and provides a platform that facilitates the analysis of large datasets. This capability allows customers to effectively survey and monitor diverse applications, optimizing the transformation of the information gathered.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Ampacimon SA specializes in manufacturing dynamic line rating systems for transmission and distribution system operators globally. Founded in 2010 and headquartered in Grace-Hollogne, Belgium, with an additional office in Cumming, Georgia, the company offers a range of innovative products designed to enhance grid infrastructure. These include ADR View, a modeling tool that utilizes historical weather data; ADR Sense, a self-powered vibration sensor; and ADR Operate, a real-time data-acquisition engine that retrieves crucial operational parameters. Additionally, Ampacimon provides ADR Trend and ADR Horizon for short- and medium-term ampacity forecasting. These solutions enable grid operators to anticipate congestion issues and implement cost-effective reconfiguration strategies, thereby addressing challenges related to aging infrastructure, congestion, and the integration of renewable energy sources.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.

Hyloris Pharmaceuticals SA is a specialty pharmaceutical company based in Liege, Belgium, founded in 2013. The company focuses on reformulating well-known pharmaceuticals to enhance their value within the healthcare system. Hyloris develops proprietary products aimed at addressing unmet medical needs across various areas, including cardiovascular diseases such as atrial fibrillation, congestive heart failure, and coronary heart disease. Its product portfolio includes intravenous ready-to-use formulations, oral liquid formulations, and topical gel and cream products. Hyloris currently offers two early commercial-stage products: Sotalol IV, intended for atrial fibrillation treatment, and Maxigesic IV, a non-opioid analgesic. The company aims to provide significant advantages over existing alternatives for patients, healthcare providers, and other stakeholders.

IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Convert Pharmaceuticals SA, founded in 2017 and based in Saint-Gilles, Belgium, focuses on the development of hypoxia-activated cytotoxic small molecules for cancer treatment. As a clinical phase I-IIa drug development company, Convert Pharmaceuticals is building a proprietary pipeline that targets tumor microenvironment-specific factors to enhance therapeutic outcomes. The company's lead product is a hypoxia-activated prodrug (HAP), designed to overcome the challenges posed by hypoxia, which often leads to resistance against conventional anti-cancer therapies. By integrating proprietary insights into the tumor microenvironment with advanced drug and biomarker development expertise, Convert Pharmaceuticals aims to provide effective and well-tolerated treatment options for cancer patients.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Preesale is a mobile-based ticket management application designed for event organizers to efficiently manage events and sell tickets. Founded in 2015 and based in Liege, Belgium, Preesale differentiates itself by allowing organizers to access cash flows before their events, enhancing revenue generation and targeting qualified leads. The application integrates seamlessly with Facebook, enabling users to create and sell tickets in under five minutes. Additionally, it provides analytical tools to track sales, facilitates communication with guests through text messages, and offers a smartphone-based ticket scanning feature for event entry. Overall, Preesale aims to improve visibility and accessibility to events, streamlining the ticketing process for both organizers and attendees.

2-Observe company is active in observational research and validation of innovative concepts in the biotechnology sector and private health care. Founded in 2010, 2-Observe company was born from the concern of its founders of meeting the needs observed in the field by providing effective solutions to improve quality of life. It was built from the experience of its associates from the medical community, the research sector and the industry field of life sciences. Jean-Philippe Hermanne MD, Internist and Head of Department of Oncology in the Centre Hospitalier Régional of Namur (Belgium), with expertise in intensive care and emergency services. Isabelle Joslet, Specialist in Public Health with a long experience as Coordinator of university research programs. Pierre Bothy, Senior Consultant in the medical device industry.

XDC S.A. operates as a Pan-European digital cinema service company. It manages operations for the deployment of digital cinema systems in theatres; and prepares and delivers digital content, which is distributed in cinemas, as well as manufactures digital cinema products, including servers, theatre management systems, projections systems, and central libraries. The company's products include CineStore Systems, a suite of digital cinema solutions; The CineStore Solo G3, a hybrid digital cinema server that offer JPEG 2000 and MPEG-2 play-back capabilities; The CineStore Audi, a device, which provides digital to analogue conversion, external analogue audio source inputs, and signal isolation; The CineStore Plaza, a hardware and software suite that enables its users to manage a cinema multiplex from a single point, as well as 3D digital cinema. XDC S.A. also provides digital content lab for the whole production, post-production, and distribution chain, as well as to synchronize various sounds and subtitle versions on the master; key management and archiving; network operations centre, which includes a spare parts logistical strategy centre and a NOC equipment centre; and XDC Entertainment, a content delivery platform to alternative content distributors/providers. The company was founded in 2004 and is based in Liège, Belgium with additional offices in Belgium, Germany, Spain, and France.